Basecamp Research raises $140M for AI-designed therapeutics

Basecamp Research, a biotechnology company based in London and Boston, has secured $140 million in oversubscribed Series C funding to advance its AI-designed therapeutics. The investment round was led by S32, with significant participation from NVIDIA, Anthropic’s Anthology Fund, the NATO Innovation Fund, and the Rockefeller Foundation.

The company utilizes its proprietary EDEN biological foundation models, trained on the Trillion Gene Atlas, to design complex DNA sequences. This technology aims to enable in vivo cell therapy, which involves reprogramming a patient’s cells directly inside their body to perform therapeutic functions. This approach seeks to reduce the high costs and manufacturing complexities associated with traditional ex vivo cell therapies.

In the broader technology landscape, leaders are addressing the challenges of AI integration. Discussions emphasize that sustainable innovation requires a foundation of trust and psychological safety to ensure successful technology adoption. Additionally, enterprises in the US and UK are shifting focus toward agentic AI, moving beyond simple chatbots to autonomous, multi-agent systems that require specialized engineering and robust data pipelines.